Despite their nearly universal activation of mammalian target of rapamycin (mTOR) signaling, glioblastomas (GBMs) are strikingly resistant to mTOR-targeted therapy. We analyzed GBM cell lines, patient-derived tumor cell cultures, and clinical samples from patients in phase 1 clinical trials, and find that the promyelocytic leukemia (PML) gene mediates resistance to mTOR-targeted therapies. Direct mTOR inhibitors and EGF receptor (EGFR) inhibitors that block downstream mTOR signaling promote nuclear PML expression in GBMs, and genetic overexpression and knockdown approaches demonstrate that PML prevents mTOR and EGFR inhibitor-dependent cell death. Low doses of the PML inhibitor, arsenic trioxide, abrogate PML expression and reverse mTOR kinase inhibitor resistance in vivo, thus markedly inhibiting tumor growth and promoting tumor cell death in mice. These results identify a unique role for PML in mTOR and EGFR inhibitor resistance and provide a strong rationale for a combination therapeutic strategy to overcome it.
We sought to prospectively evaluate the image quality and visualization of the intracranial arteries using high spatial resolution contrast-enhanced magnetic resonance angiography (CE-MRA) at 3 T and to perform intraindividual comparison with time-of-flight (TOF) MRA and multislice CT angiography (CTA). Twelve patients (5 men, 7 women, 37–71 years of age) with suspected cerebrovascular disease prospectively underwent MRA and CTA. MRA was performed on a 3 T MR system, including both 3-dimensional (3D) TOF (Voxel dimension: 0.6 × 0.5 × 0.9 mm3 in 5 minutes and 40 seconds) and 3D CE-MRA (voxel dimension: 0.7 × 0.7 × 0.8 mm3 in 20 seconds, using parallel acquisition with an acceleration factor of 4). CTA images were acquired on a 16-slice CT scanner (voxel dimension: 0.35 × 0.35 × 0.8 mm3 in 17 seconds). The image quality and visualization of up to 26 intracranial arterial segments in each study was evaluated by 2 experienced radiologists. The arterial diameter for selective intracranial arteries was measured independently on each of the 3 studies, and statistical analysis and comparative correlation was performed. A total of 312 arterial segments were examined by CE-MRA, TOF-MRA, and CTA. The majority of intracranial arteries (87%) were visualized with diagnostic image quality on CE-MRA with a significant correlation to TOF (R values = 0.84; 95% confidence interval 0.79–0.86, P < 0.0001), and to CTA (R values = 0.74; 95% confidence interavl 0.68–0.78, P < 0.001). The image quality for small intracranial arteries, including the anterior-inferior cerebellar artery, the posterior communicating artery, and the M3 branch of the middle cerebral artery, was significantly lower on CE-MRA compared with TOF and CTA (P < 0.03). There was a significant correlation for the dimensional measurements of arterial diameters at CE-MRA with TOF (r = 0.88, 95% confidence interval 0.81–0.93), and CTA (r = 0.83, 95% confidence interval 0.73–0.90). The described 3 T CE-MRA protocol, spanning from the cervical to the intracranial vessels, visualized and characterized the majority of intracranial arteries with image quality comparable with that obtained using TOF-MRA and CTA. Further clinical studies are required to establish the accuracy of the technique in a broader clinical setting.
Loss-of-function mutations at the retinoblastoma (RB1) gene are associated with increased mortality, metastasis, and poor therapeutic outcome in several cancers, including osteosarcoma. However, the mechanism(s) through which RB1 loss worsens clinical outcome remains understudied. Ubiquitin-like with PHD and Ring Finger domains 1 (UHRF1) has been identified as a critical downstream effector of the RB/E2F signaling pathway that is overexpressed in various cancers. Here, we determined the role and regulatory mechanisms of UHRF1 in rendering osteosarcoma cells more aggressive. Higher UHRF1 expression correlated with malignancy in osteosarcoma cell lines, clinical samples, and genetically engineered mouse models. Gain- and loss-of-function assays revealed that UHRF1 has cell-intrinsic and extrinsic functions promoting cell proliferation, migration, invasion, angiogenesis, and metastasis. UHRF1 overexpression induced angiogenesis by suppressing AMPK activation and Semaphorin 3E (SEMA3E) expression. Further, UHRF1-mediated migration and metastasis resulted, at least in part, through altered expression of extracellular vesicles and their cargo, including urokinase-type plasminogen activator (uPA). Novel osteosarcoma genetically engineered mouse models confirmed that knocking out Uhrf1 considerably decreased metastasis and reversed the poorer survival associated with Rb1 loss. This presents a new mechanistic insight into RB1 loss-associated poor prognosis and novel oncogenic roles of UHRF1 in the regulation of angiogenesis and exosome secretion, both critical for osteosarcoma metastasis. This provides substantial support for targeting UHRF1 or its downstream effectors as novel therapeutic options to improve current treatment for osteosarcoma.